These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23752219)

  • 41. Prescription drug spending and hospital use among Medicare beneficiaries with heart failure.
    McGee BT; Higgins MK; Phillips V; Butler J
    Res Social Adm Pharm; 2020 Oct; 16(10):1452-1458. PubMed ID: 31953113
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trends in mental health insurance benefits and out-of-pocket spending.
    McKusick DR; Mark TL; King EC; Coffey RM; Genuardi J
    J Ment Health Policy Econ; 2002 Jun; 5(2):71-8. PubMed ID: 12529560
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
    Park J; Look KA
    Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anticipatory Behavior in Response to Medicare Part D's Coverage Gap.
    Kaplan CM; Zhang Y
    Health Econ; 2017 Mar; 26(3):338-351. PubMed ID: 26749399
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?
    Mott DA; Thorpe JM; Thorpe CT; Kreling DH; Gadkari AS
    Res Social Adm Pharm; 2010 Jun; 6(2):90-9. PubMed ID: 20511108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis.
    Hartung DM; Johnston KA; McGregor JC; Bourdette DN
    Mult Scler Relat Disord; 2020 Nov; 46():102554. PubMed ID: 33032059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Part D coverage gap reform: trends in drug use and expenditures.
    Park J; Look KA
    Am J Manag Care; 2020 Aug; 26(8):349-356. PubMed ID: 32835462
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Out-of-Pocket Costs for Long-Acting Injectable and Oral Antipsychotics Among Medicare Patients With Schizophrenia.
    Doshi JA; Li P; Geng Z; Seo S; Patel C; Benson C
    Psychiatr Serv; 2024 Apr; 75(4):333-341. PubMed ID: 37960866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of U.S. federal and state generic drug policies on drug use, spending, and patient outcomes: A systematic review.
    Mishuk AU; Fasina I; Qian J
    Res Social Adm Pharm; 2020 Jun; 16(6):736-745. PubMed ID: 31445986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between the Part D coverage gap and adverse health outcomes.
    Polinski JM; Shrank WH; Glynn RJ; Huskamp HA; Christopher Roebuck M; Schneeweiss S
    J Am Geriatr Soc; 2012 Aug; 60(8):1408-17. PubMed ID: 22788544
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019.
    Dusetzina SB; Huskamp HA; Qin X; Keating NL
    JAMA; 2022 Oct; 328(15):1515-1522. PubMed ID: 36255428
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of Medicare Part D on drug and medical spending.
    Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
    N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Out-of-pocket costs and oral cancer medication discontinuation in the elderly.
    Kaisaeng N; Harpe SE; Carroll NV
    J Manag Care Spec Pharm; 2014 Jul; 20(7):669-75. PubMed ID: 24967520
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study.
    Li P; Hu T; Yu X; Chahin S; Dahodwala N; Blum M; Pettit AR; Doshi JA
    Health Serv Res; 2018 Aug; 53 Suppl 1(Suppl Suppl 1):2735-2757. PubMed ID: 28736929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.